3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow PROSTVAC: new trials by email Literature Review of PROSTVAC trials Research Report on PROSTVAC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer PROSTVAC-V, PROSTVAC-F, Nivolumab - Metastatic Hormone-Sensitive Prostate Cancer | Phase 1 | Completed | Washington University School of Medicine | 19 | 2018-09-14 | 2022-08-05 |
| Sequential Vaccinations in Prostate Cancer Patients Recombinant Fowlpox-GM-CSF, Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM), Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM) - Prostatic Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2003-05-22 | 2017-10-26 |
| A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate PROSTVAC - Prostatic Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 75 | 1994-03-01 | 2008-03-04 |
National Cancer Institute (NCI) (2) · Washington University School of Medicine (1)
United States (3)
James L Gulley, M.D. (1) · Russell Pachynski, M.D. (1)